Upadacitinib for Fistulizing Perianal Crohnâs Disease and Comorbid Enteropathic Arthritis Refractory to Combination Therapy (ACG 2026) - Aug 29, 2026 - Abstract #P1240; Pres time: Oct 11, 2026; 03:30 PM - 07:00 PM; Location: Exhibit Halls A - D (Level 3); "In addition to tumor necrosis factor-alpha inhibitors (anti-TNF), the 2025 ACG Clinical Guideline on CD now suggests upadacitinib, ustekinumab, and vedolizumab for induction of remission of FPCD: conditional recommendation - very low level of evidence...The patient failed infliximab and adalimumab therapy before developing small bowel obstructions and an abscess...Adalimumab dosing was escalated but he was ultimately switched to certolizumab pegol-azathioprine combination therapy...Figure: Figure 1: Axial contrast-enhanced CT of the pelvis demonstrating chronic left perianal fistulizing Crohn's disease with a fistulous tract extending toward the medial gluteal fold and a curvilinear seton in situ, with surrounding inflammatory soft-tissue changes. Figure: Figure 2: Timeline of immunomodulatory therapy, corticosteroid exposure, and C-reactive protein levels during the patient's clinical course, illustrating improvement in perianal disease and..."
Combination therapy • Crohn's disease • Gastroenterology • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Rheumatology • CRP
|
|
Chase Branstetter; MD; Sarah Ifteqar; MD
|